---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Phase of product development"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Phase of product development. Topics: Regulatory status: Under review; NDA submitted November 2026; Launch: Anticipated in the first half of 2027; FDA review timeline under the Commissioner's National Priority Voucher; Breakthrough Therapy designation, October 2018; 16 further topics. 20 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; NDA submitted November 2026

> “Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression November 9, 2026”
> “today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).”
> “Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD”
> “We look forward to continuing the review process, and we are focused on delivering COMP360 to patients as quickly as possible, subject to FDA approval.”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

<a id="topic-2.1.1-2"></a>

### Launch: Anticipated in the first half of 2027

> “Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval”

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx)

> “With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027.”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “On Track for COMP360 Launch in H1 2027, if FDA Approved”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

> “Compass anticipates the launch of COMP360 in the first half of 2027 subject to FDA approval and following Drug Enforcement Administration, or DEA, rescheduling.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

<a id="topic-2.1.1-3"></a>

### FDA review timeline under the Commissioner's National Priority Voucher

> “The voucher sets a one-to-two-month review target for the FDA, so there's the potential for a very rapid approval.”
> “When you look back at the limited number of precedents, they are all very different, but that sometimes encompasses both an acceptance and a review period, but there is a reasonably wide distribution around a median of around 60 days.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Potential for accelerated review, approval and rescheduling, given the National Priority Voucher (NPV) which could shorten review times to 1-2 months”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

> “The voucher program aims to shorten review to one or two months after the final application is submitted, compared with the usual 10 to 12 months, while preserving FDA safety and efficacy standards.”

Source: [Drug Discovery and Development (2026)](https://www.drugdiscoverytrends.com/psychedelic-pioneer-compass-files-for-fda-approval-as-rivals-close-in/)

<a id="topic-2.1.1-4"></a>

### Breakthrough Therapy designation, October 2018

> “has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for treatment-resistant depression”

Source: [COMPASS Pathways (2018)](https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx)

> “In 2018, we received Breakthrough Therapy designation from the U.S. Food and Drug Administration, or the FDA for COMP360 for the treatment of TRD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-2.1.1-5"></a>

### Rolling review and Commissioner's National Priority Voucher, April 2026

> “today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD).”
> “Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards.”

Source: [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx)

> “Following these data read-outs and discussions with the FDA, the FDA granted our request for a rolling review of our NDA, which is ongoing.”
> “In April 2026, the FDA issued a National Priority Voucher for COMP360 psilocybin treatment in TRD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

<a id="topic-2.1.1-6"></a>

### UK Innovation Passport under the Innovative Licensing and Access Pathway

> “We received an Innovation Passport designation from the MHRA for COMP360 for the treatment of treatment-resistant depression.”
> “The Innovation Passport is the entry point to the UK's Innovative Licensing and Access Pathway, or ILAP, a scheme intended to accelerate the time to market and facilitate patient access in the UK to certain types of medicinal products in development that target a life-threatening or seriously debilitating condition, or where there is a significant patient or public health need in the UK.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-7"></a>

### Federal rescheduling by the DEA required before marketing

> “COMP360, if approved in the United States, will require rescheduling by the DEA before it can be marketed.”
> “For any product containing psilocybin to be available for commercial marketing in the U.S., psilocybin and psilocin must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V.”
> “Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.”
> “If or when COMP360 receives FDA approval, we anticipate that the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed to patients in the U.S.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-8"></a>

### Executive Order 14401 on timely rescheduling and priority vouchers for psychedelic drugs

> “The Commissioner of Food and Drugs shall provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.”
> “The Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.”

Source: [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

> “With today’s Executive Order including the potential for accelerated regulatory and rescheduling processes, should COMP360 be approved, we will be ready to make this treatment available to patients.”

Source: [COMPASS Pathways executive order release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Commends-White-House-Executive-Order-to-Accelerate-Research-and-Access-for-Psychedelic-Treatments/default.aspx)

> “The executive order was really focused on DEA rescheduling and how to expedite that beyond or faster than the 90-day statutory timeline that the DEA has.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.1-9"></a>

### State rescheduling: over 93% of the U.S. population in states intending to reschedule within 30 days of federal action

> “But I also want to just add, in terms of timing, we also need to make sure we understand that after federal DEA reschedules, the states also need to reschedule.”
> “we now have over 93% of the U.S. population living in states that have stated that they intend to reschedule within 30 days after federal DEA.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Further, most state laws in the U.S. classify psilocybin and psilocin as Schedule I controlled substances.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-10"></a>

### Pipeline: PIVOT, a Department of Veterans Affairs trial of COMP360 in veterans with TRD

> “announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial.”
> “The multi-site, double-blind, randomized controlled trial will enroll veterans diagnosed with TRD, with or without concurrent PTSD, and will compare outcomes between two different doses of COMP360 psilocybin with the option for a second open label administration four weeks after initial dose.”
> “Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity.”

Source: [COMPASS Pathways PIVOT release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx)

> “The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.”

Source: [ClinicalTrials.gov NCT07226232](https://clinicaltrials.gov/study/NCT07226232)

<a id="topic-2.1.1-11"></a>

### Pipeline: COMP 104, a phase 2 trial in recurrent major depressive disorder

> “Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.”

Source: [ClinicalTrials.gov NCT05733546](https://clinicaltrials.gov/study/NCT05733546)

<a id="topic-2.1.1-12"></a>

### Pipeline: post-traumatic stress disorder, phase 2b/3 Redefine trial (COMP202)

> “In January 2026, the FDA accepted our IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.”

Source: [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm)

> “The primary efficacy endpoint is the change from baseline in CAPS-5 total severity score at Week 8.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder”

Source: [ClinicalTrials.gov NCT07570654](https://clinicaltrials.gov/study/NCT07570654)

> “But importantly, our very next indication is PTSD.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.1.1-13"></a>

### Pipeline: anorexia nervosa, phase 2 trial reported August 2025

> “In August 2025, we reported data from a double-blind randomized controlled Phase 2 clinical trial investigating the safety and efficacy of COMP360 psilocybin in participants with anorexia nervosa.”
> “It was a multicenter study and enrolled 32 patients.”
> “This Phase 2 clinical trial evaluated COMP360 dosed at 25mg against a control arm of participants receiving COMP360 1mg.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.1.1-14"></a>

### NDA submission within two weeks, November 2026, superseded in November 2026

> “Rolling New Drug Application (NDA) submission nearing completion, with rolling review underway. Final NDA submission will be filed in the next two weeks”

Source: [COMPASS Pathways third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000078/q32026pressrelease.htm)

<a id="topic-2.1.1-15"></a>

### NDA submission completion in the fourth quarter of 2026, March to September 2026, superseded in November 2026

> “Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4”

Source: [COMPASS Pathways fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)

> “Rolling submission and initial review are underway, with some modules of the NDA submitted and on track to complete all modules in Q4”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

> “A rolling New Drug Application, or NDA, submission and initial review with the U.S. Food and Drug Administration, or FDA, is underway and final submission remains on track to be completed in Q4, 2026.”

Source: [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm)

> “Rolling NDA submission and review underway and final submission on track to be completed in Q4”

Source: [COMPASS Pathways COMP005 52-week release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-New-52-Week-Topline-Open-Label-Data-from-Phase-3-COMP005-Trial-Demonstrates-Additional-Benefit-from-Another-COMP360-Dose-in-Part-C-Extending-Durability-Out-to-1-Year/default.aspx)

<a id="topic-2.1.1-16"></a>

### State rescheduling: approximately 90% of the U.S. patient population, August 2026, superseded in November 2026

> “Continued proactive engagement with state-level stakeholders to facilitate timely post-approval rescheduling; currently, approximately 90% of the U.S. patient population live in states that intend to reschedule within 30 days after Federal DEA”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

<a id="topic-2.1.1-17"></a>

### Launch readiness by the end of 2026, March and May 2026, superseded in August 2026

> “Compass is rapidly advancing commercial readiness efforts to be launch-ready by the end of 2026”

Source: [COMPASS Pathways fourth quarter 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)

> “Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year”

Source: [COMPASS Pathways first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/q12026pressrelease.htm)

<a id="topic-2.1.1-18"></a>

### Acceleration of commercialization readiness by 9 to 12 months, November 2025, superseded in March 2026

> “Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission”
> “Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026”

Source: [COMPASS Pathways third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1816590/000181659025000149/q32025pressrelease.htm)

<a id="topic-2.1.1-19"></a>

### Phase 3 data timing: COMP005 in the second quarter of 2025 and COMP006 in the second half of 2026, October 2024, superseded in November 2025

> “Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025”
> “COMP006 data will now be announced after 26-week time point, expected in the second half of 2026”

Source: [COMPASS Pathways third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024044400/q32024pressrelease.htm)

<a id="topic-2.1.1-20"></a>

### Phase 3 data timing: COMP005 in the fourth quarter of 2024 and COMP006 in mid-2025, August 2024, superseded in October 2024

> “Top-line pivotal COMP005 trial data is expected in the fourth quarter 2024 and COMP006 trial top-line primary endpoint is expected mid-2025.”

Source: [COMPASS Pathways second quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1816590/000162828024033854/q22024pressrelease.htm)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
